{
    "paper_id": "e999c26890e6c3b400ea74d353a4b92ff52dd684",
    "metadata": {
        "title": "Journal Pre-proof Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients - the \"Gabrin sign\"",
        "authors": [
            {
                "first": "Carlos",
                "middle": [
                    "Gustavo"
                ],
                "last": "Wambier",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sergio",
                "middle": [],
                "last": "Va\u00f1o-Galv\u00e1n",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "John",
                "middle": [],
                "last": "Mccoy",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Alba",
                "middle": [],
                "last": "Gomez-Zubiaur",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sabina",
                "middle": [],
                "last": "Herrera",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "\u00c1ngela",
                "middle": [],
                "last": "Hermosa-Gelbard",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Oscar",
                "middle": [
                    "M"
                ],
                "last": "Moreno-Arrones",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Natalia",
                "middle": [],
                "last": "Jim\u00e9nez-G\u00f3mez",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Alvaro",
                "middle": [],
                "last": "Gonz\u00e1lez-Cantero",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Pablo",
                "middle": [
                    "Fonda"
                ],
                "last": "Pascual",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Gonzalo",
                "middle": [],
                "last": "Segurado-Miravalles",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jerry",
                "middle": [],
                "last": "Shapiro",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Bibiana",
                "middle": [],
                "last": "P\u00e9rez-Garc\u00eda",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Andy",
                "middle": [],
                "last": "Goren",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "The association between SARS-CoV-2 infectiveness and the androgen pathway has 52 been previously described. 2 Androgen-mediated SARS-CoV-2 vulnerability may help 53 explain the disproportioned mortality rate among men. 3 We present further 54 epidemiologic evidence that androgen sensitivity might be associated with severe 55 symptoms leading to hospitalization due to Previously, we reported a possible association between hospitalized COVID-19 male 57 patients and AGA; however, the study was limited by its size population of 41 males. 4 58",
            "cite_spans": [
                {
                    "start": 219,
                    "end": 220,
                    "text": "3",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "In this communication, we present additional data from confirmed COVID-19 patients 59 admitted due to severity criteria (mainly low peripheral oxygen saturation) to three 60 tertiary hospitals in Madrid, Spain. The patients were randomly examined by 61 dermatologists that were assisting with the overwhelming amount of admitted 62 patients. The study took place from March 23, 2020 to April 12, 2020. Upon admission, 63 the dermatologists recorded the age, gender and alopecia diagnosis. Alopecia severity 64 was evaluated using the Hamilton-Norwood scale (HNS) for males and the Ludwig 65 scale (LS) for females. The scores were categorized into groups: \"No Alopecia\" for 66 HNS=1 or LS=0; \"Moderate AGA\" for HNS=2 or LS=1; \"Severe AGA\" for HNS>2 or LS>1. The median age of the male patients was 62.5 (IQR: 20) years (Fig1A-C). In both 73 genders age presented great variation for those with \"no alopecia\", whereas those 74 with severe AGA presented higher age distribution and median. (Fig.1D) . 75",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 988,
                    "end": 996,
                    "text": "(Fig.1D)",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "The prevalence of age matched males in a similar Caucasian population was estimated 76 to be 31-53%. 4 While in the female population the highest AGA prevalence reported 77 was 38% in patients over the age of 70. 5 These results indicate that a substantial is older age distribution in the female group compared to the male group, violin-plots 120 (C). Severity of AGA was categorized by specific gender scales: Hamilton-Norwood 121 scale (HNS) and Ludwig scale (LS) into groups: \"No Alopecia\" for HNS=1 or LS=0; 122 \"Moderate AGA\" for HNS=2 or LS=1; \"Severe AGA\" for HNS>2 or LS>1. Although age 123 was widely proportional among patients with no alopecia, moderate AGA, and severe 124 AGA, there was a slight tendency for lower age in males with moderate AGA, and in 125 females with no alopecia compared to respective severe AGA groups (D). 126 ",
            "cite_spans": [
                {
                    "start": 213,
                    "end": 214,
                    "text": "5",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": ""
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Discovering the 'heart of care",
            "authors": [
                {
                    "first": "F",
                    "middle": [
                        "D"
                    ],
                    "last": "Gabrin",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Med. Econ",
            "volume": "89",
            "issn": "",
            "pages": "20--23",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "SARS-COV-2 infection is likely to be androgen 99 mediated",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "G"
                    ],
                    "last": "Wambier",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Goren",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J. Am. Acad. Dermatol",
            "volume": "100",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1016/j.jaad.2020.04.032"
                ]
            }
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Presenting Characteristics, Comorbidities, and Outcomes 101",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Richardson",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Among 5700 Patients Hospitalized With COVID-19 in the New York City Area",
            "authors": [],
            "year": 2020,
            "venue": "JAMA",
            "volume": "102",
            "issn": "",
            "pages": "1--8",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "A preliminary observation: male pattern hair loss among 104 hospitalized COVID-19 patients in Spain -A potential clue to the role of 105 androgens in COVID-19 severity",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Goren",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J. Cosmet. Dermatol. IN PRESS",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Female Pattern Hair Loss: a clinical and 108 pathophysiological review",
            "authors": [
                {
                    "first": "P",
                    "middle": [
                        "M"
                    ],
                    "last": "Ramos",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "A"
                    ],
                    "last": "Miot",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "An. Bras. Dermatol",
            "volume": "90",
            "issn": "",
            "pages": "529--543",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Sex-Based Differences in Susceptibility to Severe 110",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Channappanavar",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Acute Respiratory Syndrome Coronavirus Infection",
            "authors": [],
            "year": 2017,
            "venue": "J. Immunol",
            "volume": "198",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF1": {
            "text": "total of 175 confirmed COVID-19 individuals were evaluated. Among the patients, 68 122 were males and 53 were females. Overall, 67% (95%CI:60%-74%) of the patients 69 presented with clinically relevant AGA. The frequency of AGA in males was: 79% 70 (95%CI: 70-85%) The frequency of AGA in females 42% (95%CI:29-55%). The median 71 age of the female patients was 71 years old with interquartile range (IQR) of 22 years. 72 4",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "78 proportion of individuals hospitalized for severe COVID-19 in your centers have AGA. 79 If the hypothesis of androgen-mediated COVID-19 severity is demonstrated in larger 80 studies, anti-androgens could potentially be used in the treatment of COVID-19. A 81 study on male mice administered a lethal dosage of SARS-CoV, demonstrated a 82 protective effect of prophylactic anti-androgen (flutamide) therapy in 20% of the 83 mice. 6 Anti-androgen treatments could be theoretically studied in the treatment and 84 prophylaxis of severe COVID-19 are indicated in Fig.2. The sample size and lack of a 85 control group and outcomes are limitations of this study. Since dermatologists actively 86 graded AGA, observer bias was possible. The precise AGA rate in age-matched, not-87 admitted COVID-19 population is still unknown to draw further conclusions. Future 88 studies could evaluate if lung involvement correlates with severity of AGA, or if the 89 proportion of AGA is higher in intensive care/fatal COVID-19. AGA severity reflects 90 androgen activity over age, which are two vulnerability characteristics for COVID-19. 91 AGA is a primary individual characteristic, different from telogen effluvium which 92 occurs after months of the stress of illness. 93Finally, as Dr. Gabrin was the first physician to die from COVID-19 in the US, we 94propose the use of the eponym the \"Gabrin sign\" to visually identify patients at higher 95 risk for severe symptoms following COVID-19 infection. Epidemiological characteristics of 175 individuals hospitalized due to severe 116 symptoms of COVID-19 from March 23, 2020 to April 12, 2020. The study population 117 had male:women ratio of 2.3:1, single pie-chart (A). 42% of the females and 79% of the 118 males presented with androgenetic alopecia (AGA), two pie-charts (B). Notably, there 119",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Possible targets of the androgen pathway for severe acute respiratory 127 syndrome coronavirus (SARS-CoV)-2 prophylaxis and adjuvant therapy. Anti-androgen 128 therapies include: GnRH analogues (Degarelix, Goserelin, Leuprolide, Leuprorelin, 129 Nafarelin), which stop LH secretion and induce chemical castration. Testosterone is 130 regarded as the main androgen hormone, its production is inhibited by Ketoconazole, 131 an inhibitor of steroidogenesis. Dutasteride and Finasteride, 5-alpha-reductase 132 inhibitors, target synthesis of dihydrotestosterone (DHT), the most potent intrinsic 133 androgen hormone. Androgen receptor inhibitors may be steroidal (Abiraterone, 134 Cyproterone, Nomegestrol, or Spironolactone), or non-steroidal (Apalutamide, 135",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Infectious Diseases Unit, Ram\u00f3n y Cajal Hospital, Madrid, Spain 15 6 Dermatology Department, Hospital Central de la Defensa, Madrid, Spain 16 7 Ronald O. Perelman Department of Dermatology at the New York University School of Conflicts of Interest: None declared.Dear Editor, Dr Frank Gabrin was the first American physician to die due to severe 49 acute respiratory syndrome coronavirus (SARS-CoV)-2 infection. Dr. Gabrin suffered 50 from androgenetic alopecia and was a long-term survivor of bilateral testicular cancer. 1 51",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}